{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T12:07:41Z","timestamp":1788782861043,"version":"build-2803163510"},"reference-count":180,"publisher":"American Chemical Society (ACS)","issue":"9","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/na","name":"Paediatric precision oncology program, INdividualized Therapy FOr Relapsed Malignancies in Childhood (INFORM) in Europe.","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/na","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The design and development of suitable dosage forms for pediatric patients face myriad challenges. Compared to other dosage forms, oral dosage forms are widely used and accepted in pediatric patients. However, oral dosage forms have their own challenges, which include the requirement for dose flexibility, limited bioavailability due to the poor solubility of the drug, safety concerns regarding excipients, and drug administration challenges for pediatric patients. The importance of research in drug delivery of anticancer drugs has increased due to poor drug solubility and the limited availability of pharmacokinetic data in pediatric patients. The poor solubility of anticancer drugs necessitates higher doses, leading to increased episodes of adverse effects. Furthermore, administering these drugs in the fed state results in bioavailability variations compared to the fasting state, which becomes more critical for pediatric patients. Therefore, it is essential to screen formulation strategies for these drugs to improve their bioavailability in the early stages of development. This review outlines key concerns of pediatric patients receiving long-term cancer drug therapy, including physiological and pharmacological challenges in the pediatric population, the impact of food on drug efficacy, and potential adverse effects associated with it. It also highlights various formulation strategies aimed at mitigating food-related variability through bioavailability enhancement. Furthermore, the review addresses the safety levels of excipients and development of age-appropriate dosage forms for the pediatric population.<\/jats:p>","DOI":"10.1021\/acs.molpharmaceut.5c00642","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T07:27:41Z","timestamp":1788247661000},"page":"4394-4415","source":"Crossref","is-referenced-by-count":0,"title":["Insight\ninto the Development of Desirable Dosage Forms\nand Bioenabling Strategies to Improve the Food Effect of Anticancer\nDrugs for the Pediatric Population"],"prefix":"10.1021","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6339-513X","authenticated-orcid":true,"given":"Abhijeet","family":"Upadhye","sequence":"first","affiliation":[{"name":"Birla Institute of Technology and Science , , Vidya Vihar Campus , , ,","place":["Pilani, Rajasthan, India, 333031"]},{"name":"Torrent Research Center , Village Bhat , , ,","place":["Dist. Gandhinagar, Gujarat, India, 382428"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8988-046X","authenticated-orcid":true,"given":"Murali Monohar","family":"Pandey","sequence":"additional","affiliation":[{"name":"Birla Institute of Technology and Science , , Vidya Vihar Campus , , ,","place":["Pilani, Rajasthan, India, 333031"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"issue":"1","key":"2026090707080706600_cit1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jconrel.2013.04.020","article-title":"Oral Delivery of Anti-cancer\nDrugs: Challenges and Opportunities","volume":"170","author":"Thanki","year":"2013","journal-title":"J. Controlled\nRelease"},{"issue":"11","key":"2026090707080706600_cit2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.43198","article-title":"Global\nDisparities of Cancer and Its Projected Burden in 2050","volume":"7","author":"Bizuayehu","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"2026090707080706600_cit3","unstructured":"WHO Fact-Sheets Detail for Cancer-in-Children. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cancer-in-children, https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cancer-in-children (accessed May 31, 2026)."},{"issue":"1","key":"2026090707080706600_cit4","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.therap.2022.11.010","article-title":"Paediatric Drug Development\nand Evaluation: Existing Challenges and Recommendations","volume":"78","author":"Kaguelidou","year":"2023","journal-title":"Therapies"},{"issue":"1","key":"2026090707080706600_cit5","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3322\/caac.20004","article-title":"Patient Adherence\nand Persistence\nwith Oral Anti-cancer Treatment","volume":"59","author":"Ruddy","year":"2009","journal-title":"Ca-Cancer J.\nClin."},{"issue":"9","key":"2026090707080706600_cit6","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/sj.bjc.6600591","article-title":"Oral Cancer Treatment:\nDevelopments in Chemotherapy\nand Beyond","volume":"87","author":"O\u2019Neill","year":"2002","journal-title":"Br. J. Cancer"},{"key":"2026090707080706600_cit7","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1093\/jnci\/94.9.652","article-title":"Adherence to Therapy\nwith Oral Antineoplastic Agents","volume":"94","author":"Partridge","year":"2002","journal-title":"J. Natl. Cancer\nInst."},{"issue":"8","key":"2026090707080706600_cit8","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.ctrv.2010.04.005","article-title":"Anti-cancer Oral Therapy: Emerging\nRelated Issues","volume":"36","author":"Banna","year":"2010","journal-title":"Cancer Treat. Rev."},{"issue":"7","key":"2026090707080706600_cit9","first-page":"55","article-title":"Pharmacoeconomic\nand Clinical Outcomes\nin Oncology Using Oral Chemotherapy","volume":"15","author":"Navarro","year":"2002","journal-title":"Manag.\nCare Interface"},{"issue":"2","key":"2026090707080706600_cit10","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1097\/01.NCC.0000265009.33053.2d","article-title":"Facilitating\nOral Chemotherapy Treatment and Compliance Through Patient\/Family-Focused\nEducation","volume":"30","author":"Moore","year":"2007","journal-title":"Cancer Nurs."},{"key":"2026090707080706600_cit11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1188\/03.CJON.S6.5-9","article-title":"A Changing\nParadigm for Cancer Treatment: The Advent of New Oral Chemotherapy\nAgents","volume":"7","author":"Bedell","year":"2003","journal-title":"Clin. J. Oncol. Nurs."},{"issue":"8","key":"2026090707080706600_cit12","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1002\/ijc.25026","article-title":"Tumor Angiogenesis and Novel Antiangiogenic\nStrategies","volume":"126","author":"Gordon","year":"2010","journal-title":"Int. J. Cancer"},{"issue":"1\u20132","key":"2026090707080706600_cit13","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.ijpharm.2006.01.028","article-title":"Enhanced Bioavailability of Tamoxifen\nafter Oral Administration of Tamoxifen with Quercetin in Rats","volume":"313","author":"Shin","year":"2006","journal-title":"Int. J. Pharm."},{"issue":"2","key":"2026090707080706600_cit14","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1021\/acs.molpharmaceut.5b00837","article-title":"Improving Oral Bioavailability\nof Sorafenib by Optimizing the \u201cSpring\u201d and \u201cParachute\u201d\nBased on Molecular Interaction Mechanisms","volume":"13","author":"Liu","year":"2016","journal-title":"Mol.\nPharmaceutics"},{"issue":"1","key":"2026090707080706600_cit15","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.dmpk.2019.08.006","article-title":"Influence of Gastrointestinal\nActivity on the Absorption of Nilotinib","volume":"35","author":"Sasaki","year":"2020","journal-title":"Drug\nMetab. Pharmacokinet."},{"issue":"1","key":"2026090707080706600_cit16","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13065-018-0434-1","article-title":"Enhancement\nof Oral\nBioavailability of Doxorubicin through Surface Modified Biodegradable\nPolymeric Nanoparticles","volume":"12","author":"Ahmad","year":"2018","journal-title":"Chem. Cent. J."},{"issue":"2","key":"2026090707080706600_cit17","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s00228-011-1102-8","article-title":"The Role of Diet on\nthe Clinical\nPharmacology of Oral Antineoplastic Agents","volume":"68","author":"Ruggiero","year":"2012","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"15","key":"2026090707080706600_cit18","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.2165\/00003088-200443150-00005","article-title":"Effects of Food on the Clinical Pharmacokinetics\nof\nAnti-cancer Agents","volume":"43","author":"Singh","year":"2004","journal-title":"Clin. Pharmacokinet."},{"issue":"2","key":"2026090707080706600_cit19","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3390\/children2020244","article-title":"Influence\nof Food on Paediatric Gastrointestinal Drug Absorption Following Oral\nAdministration: A Review","volume":"2","author":"Batchelor","year":"2015","journal-title":"Children"},{"issue":"1","key":"2026090707080706600_cit20","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/bf00553164","article-title":"Effect of\nFood on Pharmacokinetics of Chlorambucil and Its Main Metabolite,\nPhenylacetic Acid Mustard","volume":"27","author":"Ehrsson","year":"1984","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"2","key":"2026090707080706600_cit21","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1093\/ajcn\/79.2.345a","article-title":"Handbook\nof Food-Drug Interactions","volume":"79","author":"Vanderveen","year":"2004","journal-title":"Am. J. Clin. Nutr."},{"issue":"2\u20133","key":"2026090707080706600_cit22","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S0169-409X(97)00040-9","article-title":"The Effects\nof Diet, Aging and Disease-States on Presystemic Elimination and Oral\nDrug Bioavailability in Humans","volume":"27","author":"Wilkinson","year":"1997","journal-title":"Adv. Drug Deliv.\nRev."},{"issue":"8","key":"2026090707080706600_cit23","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.3390\/nu17081326","article-title":"Breastfeeding:\nThe Multifaceted Impact on Child Development and Maternal Well-Being","volume":"17","author":"Purkiewicz","year":"2025","journal-title":"Nutrients"},{"key":"2026090707080706600_cit24","doi-asserted-by":"publisher","first-page":"105828","DOI":"10.1016\/j.ejps.2021.105828","article-title":"Drug Solubilization during Simulated\nPediatric Gastro-Intestinal\nDigestion","volume":"162","author":"Kofoed-Djursner","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"issue":"2","key":"2026090707080706600_cit25","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.ijpharm.2014.02.046","article-title":"Paediatric\nBiopharmaceutics Classification System: Current Status and Future\nDecisions","volume":"469","author":"Batchelor","year":"2014","journal-title":"Int. J. Pharm."},{"key":"2026090707080706600_cit26","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.addr.2021.02.001","article-title":"Current Challenges\nand Future Perspectives in Oral Absorption Research: An Opinion of\nthe UNGAP Network","volume":"171","author":"Vinarov","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2026090707080706600_cit27","doi-asserted-by":"publisher","first-page":"100186","DOI":"10.1016\/j.nxnano.2025.100186","article-title":"An Overview on Developing\nthe Formulation to Keep Away\nthe Food Impact on Absorption","volume":"7","author":"Magar","year":"2025","journal-title":"Next Nanotechnol."},{"issue":"8","key":"2026090707080706600_cit28","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1080\/17425247.2020.1776261","article-title":"The Use of Cyclodextrin Inclusion\nComplexes to Improve Anti-cancer Drug Profiles: A Systematic Review","volume":"17","author":"Gandhi","year":"2020","journal-title":"Expert Opin. Drug Deliv."},{"issue":"4","key":"2026090707080706600_cit29","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1111\/jphp.12955","article-title":"Biopharmaceutical Considerations\nin Paediatrics with a View to the Evaluation of Orally Administered\nDrug Products - a PEARRL Review","volume":"71","author":"Guimara\u0303es","year":"2019","journal-title":"J. Pharm. Pharmacol."},{"issue":"11","key":"2026090707080706600_cit30","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1016\/j.clinthera.2012.09.014","article-title":"Summary of the National\nInstitute of Child Health and\nHuman Development-Best Pharmaceuticals for Children Act Pediatric\nFormulation Initiatives Workshop-Pediatric Biopharmaceutics Classification\nSystem Working Group","volume":"34","author":"Abdel-Rahman","year":"2012","journal-title":"Clin. Ther."},{"issue":"8","key":"2026090707080706600_cit31","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1211\/jpp.59.8.0001","article-title":"Developing\nPaediatric Medicines: Identifying the Needs and Recognizing the Challenges","volume":"59","author":"Ernest","year":"2007","journal-title":"J. Pharm. Pharmacol."},{"issue":"1","key":"2026090707080706600_cit32","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s43094-024-00579-4","article-title":"Nanocrystals: An Emerging Paradigm for Cancer Therapeutics","volume":"10","author":"Patel","year":"2024","journal-title":"Futur. J. Pharm. Sci."},{"key":"2026090707080706600_cit33","doi-asserted-by":"publisher","first-page":"1232012","DOI":"10.3389\/fddev.2023.1232012","article-title":"Lipid-Based\nOral Formulation in Capsules to Improve the Delivery of Poorly Water-Soluble\nDrugs","volume":"3","author":"Mohite","year":"2023","journal-title":"Front. Drug Deliv."},{"issue":"16","key":"2026090707080706600_cit34","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1002\/cncr.28748","article-title":"Declining\nChildhood and Adolescent Cancer Mortality","volume":"120","author":"Smith","year":"2014","journal-title":"Cancer"},{"key":"2026090707080706600_cit35","unstructured":"National Cancer Institute.\n          . Cancer in\nChildren and Adolescents, 2025. https:\/\/www.cancer.gov\/types\/childhood-cancers (accessed May 31, 2026)."},{"issue":"3","key":"2026090707080706600_cit36","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/bcp.12305","article-title":"Clinical Trials in Children","volume":"79","author":"Joseph","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"4","key":"2026090707080706600_cit37","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.phoj.2020.06.005","article-title":"WHO Global Initiative for Childhood Cancer - India\nResponds","volume":"5","author":"Pediatric Hematology Oncology, Chapter of Indian Academy of Pediatrics (PHO IAP), Indian Pediatric Oncology Group (InPOG), Cankids Kidscan Representing Civil Society & Patient Groups.","year":"2020","journal-title":"Pediatr. Hematol. Oncol. J."},{"issue":"6","key":"2026090707080706600_cit38","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1158\/1055-9965.EPI-19-0941","article-title":"Cancer Progress\nand Priorities: Childhood Cancer","volume":"29","author":"Lupo","year":"2020","journal-title":"Cancer Epidemiol.,\nBiomarkers Prev."},{"key":"2026090707080706600_cit39","doi-asserted-by":"crossref","unstructured":"Schneible, S.\n          ; American Association for Cancer Research.. https:\/\/www.aacr.org\/blog\/2025\/09\/05\/pediatric-cancers-aftershocks-the-challenges-for-survivors-beyond-childhood (accessed May 31, 2026).","DOI":"10.1057\/978-1-349-96132-0_12824"},{"issue":"15","key":"2026090707080706600_cit40","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1056\/NEJMsa060185","article-title":"Chronic Health Conditions\nin Adult Survivors of Childhood\nCancer","volume":"355","author":"Oeffinger","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"2026090707080706600_cit41","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.jpeds.2011.03.046","article-title":"Distinct Impact of Imatinib on Growth\nat Prepubertal and Pubertal Ages of Children with Chronic Myeloid\nLeukemia","volume":"159","author":"Shima","year":"2011","journal-title":"J. Pediatr."},{"issue":"9","key":"2026090707080706600_cit42","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nrclinonc.2011.95","article-title":"Challenging\nIssues in Pediatric Oncology","volume":"8","author":"Pui","year":"2011","journal-title":"Nat. Rev. Clin.\nOncol."},{"issue":"20","key":"2026090707080706600_cit43","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1200\/JCO.20.03681","article-title":"Rethinking\nSuccess in Pediatric Oncology: Beyond 5-Year Survival","volume":"39","author":"Williams","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"2026090707080706600_cit44","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1001\/jamaoncol.2019.5582","article-title":"Life Expectancy of Adult Survivors of Childhood Cancer\nOver 3 Decades","volume":"6","author":"Yeh","year":"2020","journal-title":"JAMA Oncol."},{"issue":"3","key":"2026090707080706600_cit45","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3322\/caac.21273","article-title":"Improving\nthe Outcome for Children with Cancer: Development of Targeted New\nAgents","volume":"65","author":"Adamson","year":"2015","journal-title":"Ca-Cancer J. Clin."},{"issue":"2","key":"2026090707080706600_cit46","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.ejca.2014.10.029","article-title":"Creating a\nUnique, Multi-Stakeholder Paediatric Oncology Platform to Improve\nDrug Development for Children and Adolescents with Cancer","volume":"51","author":"Vassal","year":"2015","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"2026090707080706600_cit47","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/psp4.12366","article-title":"Children Are Not Small Adults, but Can We Treat Them\nAs Such?","volume":"8","author":"Krekels","year":"2019","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"issue":"4","key":"2026090707080706600_cit48","doi-asserted-by":"publisher","first-page":"262","DOI":"10.5863\/1551-6776-19.4.262","article-title":"Developmental\nPharmacokinetics in Pediatric Populations","volume":"19","author":"Lu","year":"2014","journal-title":"J.\nPediatr. Pharmacol. Ther."},{"issue":"1","key":"2026090707080706600_cit49","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/pr.2014.143","article-title":"Dosing in Neonates: Special Considerations\nin Physiology\nand Trial Design","volume":"77","author":"Ku","year":"2015","journal-title":"Pediatr. Res."},{"issue":"3","key":"2026090707080706600_cit50","doi-asserted-by":"publisher","first-page":"170","DOI":"10.5863\/1551-6776-16.3.170","article-title":"Neonatal Pharmacology:\nExtensive\nInterindividual Variability Despite Limited Size","volume":"16","author":"Tayman","year":"2011","journal-title":"J. Pediatr. Pharmacol. Ther."},{"issue":"1","key":"2026090707080706600_cit51","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3390\/pharmaceutics3010053","article-title":"Factors and Mechanisms\nfor Pharmacokinetic Differences\nbetween Pediatric Population and Adults","volume":"3","author":"Fernandez","year":"2011","journal-title":"Pharmaceutics"},{"issue":"6","key":"2026090707080706600_cit52","doi-asserted-by":"publisher","first-page":"926","DOI":"10.3390\/children10060926","article-title":"Impact\nof Protein Binding Capacity and Daily Dosage of a Drug on Total Serum\nBilirubin Levels in Susceptible Infants","volume":"10","author":"Lee","year":"2023","journal-title":"Children"},{"issue":"5","key":"2026090707080706600_cit53","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/S0169-409X(03)00030-9","article-title":"Pharmacokinetics in the Newborn","volume":"55","author":"Alcorn","year":"2003","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"6403","key":"2026090707080706600_cit54","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1136\/bmj.287.6403.1424","article-title":"Chloramphenicol Toxicity\nin Neonates:\nIts Incidence and Prevention","volume":"287","author":"Mulhall","year":"1983","journal-title":"Br. Med. J."},{"issue":"4","key":"2026090707080706600_cit55","doi-asserted-by":"publisher","first-page":"F294","DOI":"10.1136\/adc.2004.056317","article-title":"Aminoglycoside Extended\nInterval Dosing in Neonates Is Safe and Effective: A Meta-Analysis","volume":"90","author":"Nestaas","year":"2005","journal-title":"Arch. Dis. Child. Fetal Neonatal Ed."},{"key":"2026090707080706600_cit56","doi-asserted-by":"publisher","first-page":"19","DOI":"10.21037\/pm-22-11","article-title":"Pharmacokinetics of Drugs: Newborn\nPerspective","volume":"7","author":"Bansal","year":"2024","journal-title":"Pediatr. Med."},{"issue":"4","key":"2026090707080706600_cit57","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/S0022-3476(89)80302-6","article-title":"Gestational\nEvolution of Small Intestine Motility in Preterm and Term Infants","volume":"115","author":"Berseth","year":"1989","journal-title":"J. Pediatr."},{"key":"2026090707080706600_cit58","first-page":"2","article-title":"Paediatric anaesthesia review","volume":"8","author":"Rusy","year":"1998","journal-title":"Update Anaesth."},{"issue":"1","key":"2026090707080706600_cit59","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s11096-010-9455-0","article-title":"Review\nof Paediatric Gastrointestinal Physiology Data Relevant to Oral Drug\nDelivery","volume":"33","author":"Kaye","year":"2011","journal-title":"Int. J. Clin. Pharm."},{"issue":"1\u20132","key":"2026090707080706600_cit60","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ijpharm.2010.04.048","article-title":"Specific Aspects\nof Gastro-Intestinal Transit in Children for Drug Delivery Design","volume":"395","author":"Bowles","year":"2010","journal-title":"Int. J. Pharm."},{"issue":"4","key":"2026090707080706600_cit61","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/cpdd.351","article-title":"Food Effect\non Oral Bioavailability: Old and New Questions","volume":"6","author":"Yan","year":"2017","journal-title":"Clin. Pharmacol. Drug Dev."},{"issue":"8","key":"2026090707080706600_cit62","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1002\/jcph.2456","article-title":"Food Effect\nin Pediatric Populations: Current Practice, Challenges, and Future\nPotential for Use of Physiologically Based Biopharmaceutics Modeling","volume":"64","author":"Parrott","year":"2024","journal-title":"J. Clin. Pharmacol."},{"issue":"1","key":"2026090707080706600_cit63","doi-asserted-by":"publisher","first-page":"81","DOI":"10.4155\/tde.11.142","article-title":"The Effect of Food on the Oral Bioavailability\nof Drugs: A Review of Current Developments and Pharmaceutical Technologies\nfor Pharmacokinetic Control","volume":"3","author":"Yasuji","year":"2012","journal-title":"Ther. Deliv."},{"key":"2026090707080706600_cit64","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2147\/DDDT.S497515","article-title":"Impact of Food Physical\nProperties on Oral Drug Absorption: A Comprehensive\nReview","volume":"19","author":"Wang","year":"2025","journal-title":"Drug Des. Devel. Ther."},{"key":"2026090707080706600_cit65","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ejpb.2016.11.034","article-title":"Food, Gastrointestinal\nPH, and Models of Oral Drug Absorption","volume":"112","author":"Abuhelwa","year":"2017","journal-title":"Eur.\nJ. Pharm. Biopharm."},{"issue":"1","key":"2026090707080706600_cit66","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40795-024-00824-2","article-title":"Correlating\nFood and Nutritional\nPatterns with Cancers in the Pediatric Oncology Population at Two\nSpecialized Hospitals in Tanzania","volume":"10","author":"Monko","year":"2024","journal-title":"BMC Nutr."},{"issue":"5","key":"2026090707080706600_cit67","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/jcph.1359","article-title":"Accelerating Drug\nDevelopment in Pediatric Oncology\nWith the Clinical Pharmacology Storehouse","volume":"59","author":"Shebley","year":"2019","journal-title":"J.\nClin. Pharmacol."},{"issue":"17","key":"2026090707080706600_cit68","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1007\/s40265-017-0832-z","article-title":"A Review of Food-Drug\nInteractions on Oral Drug Absorption","volume":"77","author":"Deng","year":"2017","journal-title":"Drugs"},{"issue":"3","key":"2026090707080706600_cit69","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1158\/2159-8290.CD-20-0779","article-title":"Opportunities\nand Challenges in Drug Development for Pediatric Cancers","volume":"11","author":"Laetsch","year":"2021","journal-title":"Cancer Discov."},{"issue":"1","key":"2026090707080706600_cit70","doi-asserted-by":"publisher","first-page":"188319","DOI":"10.1016\/j.bbcan.2019.188319","article-title":"Harnessing the Therapeutic\nPotential\nof Anti-cancer Drugs through Amorphous Solid Dispersions","volume":"1873","author":"Gala","year":"2020","journal-title":"Biochim. Biophys. Acta, Rev. Cancer"},{"issue":"1\u20132","key":"2026090707080706600_cit71","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ijpharm.2016.04.013","article-title":"Prediction of Positive Food Effect:\nBioavailability\nEnhancement of BCS Class II Drugs","volume":"506","author":"Raman","year":"2016","journal-title":"Int. J. Pharm."},{"issue":"3","key":"2026090707080706600_cit72","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.ajps.2020.07.003","article-title":"Recent Advances of\nSorafenib Nanoformulations for Cancer Therapy:\nSmart Nanosystem and Combination Therapy","volume":"16","author":"Chen","year":"2021","journal-title":"Asian\nJ. Pharm. Sci."},{"key":"2026090707080706600_cit73","unstructured":"Novartis Pharmaceuticals Corporation.\n          . Drug Label Information,\nNilotinib\nCapsule (TASIGNA) Dailymed 2024. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=6093952a-5248-45cb-ad17-33716a411146 (accessed May 31, 2026)."},{"key":"2026090707080706600_cit74","doi-asserted-by":"publisher","first-page":"1015200","DOI":"10.3389\/fonc.2022.1015200","article-title":"Therapeutic Drug Monitoring\nfor Cytotoxic Anti-cancer Drugs: Principles and Evidence-Based Practices","volume":"12","author":"Smita","year":"2022","journal-title":"Front. Oncol."},{"issue":"1","key":"2026090707080706600_cit75","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40780-019-0155-1","article-title":"Relationship\nbetween the Effects of Food on the Pharmacokinetics of Oral Antineoplastic\nDrugs and Their Physicochemical Properties","volume":"5","author":"Omachi","year":"2019","journal-title":"J. Pharm. Heal. Care Sci."},{"issue":"4","key":"2026090707080706600_cit76","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/jphp.12957","article-title":"Food for\nThought: Formulating Away the Food Effect - a PEARRL Review","volume":"71","author":"O\u2019Shea","year":"2019","journal-title":"J. Pharm. Pharmacol."},{"key":"2026090707080706600_cit77","unstructured":"Bayer HealthCare Pharmaceuticals Inc.\n          . Drug Label Information,\nSorafenib Tablet (NEXAVAR) 2005. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=b50667e4-5ebc-4968-a646-d605058dbef0 (accessed May 31, 2026)."},{"key":"2026090707080706600_cit78","doi-asserted-by":"publisher","first-page":"114868","DOI":"10.1016\/j.ejpb.2025.114868","article-title":"Towards the Development of a Standard\nToolbox for Compatibility Testing of Pediatric Drug Products with\nCommon Dosing Vehicles - Fruit Juice, Apple Sauce, Yogurt, and Pudding","volume":"217","author":"Eckert","year":"2025","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"6","key":"2026090707080706600_cit79","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1021\/jm301721e","article-title":"Optimizing Solubility and Permeability\nof a Biopharmaceutics Classification System (BCS) Class 4 Antibiotic\nDrug Using Lipophilic Fragments Disturbing the Crystal Lattice","volume":"56","author":"Tehler","year":"2013","journal-title":"J. Med. Chem."},{"issue":"7","key":"2026090707080706600_cit80","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.3390\/pharmaceutics13071035","article-title":"Meta-Analysis of Food Effect on Oral Absorption of\nEfflux Transporter Substrate Drugs: Does Delayed Gastric Emptying\nInfluence Drug Transport Kinetics","volume":"13","author":"Sharma","year":"2021","journal-title":"Pharmaceutics"},{"issue":"9","key":"2026090707080706600_cit81","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.3390\/pharmaceutics14091807","article-title":"Fast-Fed Variability:\nInsights into Drug Delivery, Molecular Manifestations, and Regulatory\nAspects","volume":"14","author":"Rangaraj","year":"2022","journal-title":"Pharmaceutics"},{"key":"2026090707080706600_cit82","doi-asserted-by":"publisher","first-page":"121695","DOI":"10.1016\/j.ijpharm.2022.121695","article-title":"Bio-Enabling\nStrategies to Mitigate the Pharmaceutical Food Effect: A Mini Review","volume":"619","author":"Meola","year":"2022","journal-title":"Int. J. Pharm."},{"issue":"2","key":"2026090707080706600_cit83","doi-asserted-by":"publisher","first-page":"30","DOI":"10.19080\/GJPPS.2017.03.555608","article-title":"\u201cSolid Dispersion - a Novel Approach for Enhancement\nof Bioavailability of Poorly Soluble Drugs in Oral Drug Delivery System.\u201d","volume":"3","author":"Kumar Sarangi","year":"2017","journal-title":"Glob. J. Pharm. Pharm. Sci."},{"issue":"1","key":"2026090707080706600_cit84","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s40199-022-00440-0","article-title":"Solid Dispersion Technology as a\nFormulation Strategy for the Fabrication of Modified Release Dosage\nForms: A Comprehensive Review","volume":"30","author":"Patel","year":"2022","journal-title":"DARU J. Pharm.\nSci."},{"key":"2026090707080706600_cit85","doi-asserted-by":"publisher","first-page":"119836","DOI":"10.1016\/j.ijpharm.2020.119836","article-title":"Preparation and\nCharacterization of Sorafenib-Loaded\nMicroprecipitated Bulk Powder for Enhancing Oral Bioavailability","volume":"589","author":"Park","year":"2020","journal-title":"Int. J. Pharm."},{"issue":"1\u20132","key":"2026090707080706600_cit86","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.ijpharm.2017.07.010","article-title":"Improving the Solubility\nof Nilotinib through Novel Spray-Dried Solid Dispersions","volume":"529","author":"Herbrink","year":"2017","journal-title":"Int. J. Pharm."},{"key":"2026090707080706600_cit87","doi-asserted-by":"publisher","first-page":"121216","DOI":"10.1016\/j.ijpharm.2021.121216","article-title":"Efficient\nDevelopment of Sorafenib Tablets with Improved Oral Bioavailability\nEnabled by Coprecipitated Amorphous Solid Dispersion","volume":"610","author":"Song","year":"2021","journal-title":"Int. J. Pharm."},{"key":"2026090707080706600_cit88","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.powtec.2015.04.044","article-title":"Preparation\nand Characterization\nof Solid Dispersion Using a Novel Amphiphilic Copolymer to Enhance\nDissolution and Oral Bioavailability of Sorafenib","volume":"283","author":"Truong","year":"2015","journal-title":"Powder Technol."},{"key":"2026090707080706600_cit89","unstructured":"Novartis Pharmaceuticals Corporation.\n          . A. N. 022068. Clinical Pharmacology\nBiopharmaceutics Review(s); Tasigna Capsules (Nilotinib Capsules), 2007. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2007\/022068s000_ClinPharmR.pdf (accessed May 31, 2026)."},{"issue":"15_suppl","key":"2026090707080706600_cit90","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.32.15_suppl.e13551","article-title":"Comparable Pharmacokinetics of 85\nMg RightSize Nilotinib (XS003) and 150 Mg Tasigna in Healthy Volunteers\nUsing a Hybrid Nanoparticle-Based Formulation Platform for Protein\nKinase Inhibitors","volume":"32","author":"Andersson","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"2026090707080706600_cit91","doi-asserted-by":"publisher","first-page":"100980","DOI":"10.1016\/j.ajps.2024.100980","article-title":"Biopharmaceutical and\nPharmacokinetic Attributes to Drive Nanoformulations\nof Small Molecule Tyrosine Kinase Inhibitors","volume":"19","author":"Mukherjee","year":"2024","journal-title":"Asian J. Pharm. Sci."},{"issue":"1","key":"2026090707080706600_cit92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00280-025-04777-6","article-title":"Pharmacokinetic Profile of Novel Reduced-Dose Danziten (Nilotinib\nTablets) versus Tasigna (Nilotinib Capsules): In Vivo Bioequivalence\nand Population Pharmacokinetic Analysis","volume":"95","author":"Mauro","year":"2025","journal-title":"Cancer\nChemother. Pharmacol."},{"issue":"4","key":"2026090707080706600_cit93","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1002\/cpt.3002","article-title":"Key Pharmacokinetic\nParameters of 74 Pediatric Anti-cancer Drugs Providing Assistance\nin Preclinical Studies","volume":"114","author":"Jamaladdin","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1\u20132","key":"2026090707080706600_cit94","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ijpharm.2010.07.044","article-title":"Nanocrystals:\nIndustrially Feasible Multifunctional\nFormulation Technology for Poorly Soluble Actives","volume":"399","author":"Shegokar","year":"2010","journal-title":"Int. J. Pharm."},{"key":"2026090707080706600_cit95","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2147\/IJN.S595","article-title":"Nanocrystal Technology,\nDrug Delivery and Clinical Applications","volume":"3","author":"Mu\u0308ller","year":"2008","journal-title":"Int.\nJ. Nanomedicine"},{"issue":"8","key":"2026090707080706600_cit96","doi-asserted-by":"publisher","first-page":"14451","DOI":"10.3390\/molecules200814451","article-title":"Absorption-Enhancing\nEffects of Bile\nSalts","volume":"20","author":"Moghimipour","year":"2015","journal-title":"Molecules"},{"key":"2026090707080706600_cit97","first-page":"95","article-title":"Nanosizing\nof Drugs: Effect on Dissolution Rate","volume":"10","author":"Dizaj","year":"2015","journal-title":"Res. Pharm.\nSci."},{"issue":"1","key":"2026090707080706600_cit98","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ajps.2014.08.005","article-title":"Nanocrystals\nfor Enhancement of Oral Bioavailability\nof Poorly Water-Soluble Drugs","volume":"10","author":"Junyaprasert","year":"2015","journal-title":"Asian J. Pharm.\nSci."},{"key":"2026090707080706600_cit99","doi-asserted-by":"publisher","first-page":"111377","DOI":"10.1016\/j.colsurfb.2020.111377","article-title":"Poly-Tannic Acid Coated\nPaclitaxel Nanocrystals for Combinational Photothermal-Chemotherapy","volume":"197","author":"Huang","year":"2021","journal-title":"Colloids Surf., B"},{"issue":"1\u20132","key":"2026090707080706600_cit100","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.ijpharm.2011.08.003","article-title":"Bioavailability and\nPharmacokinetics of Sorafenib Suspension,\nNanoparticles and Nanomatrix for Oral Administration to Rat","volume":"419","author":"Wang","year":"2011","journal-title":"Int. J. Pharm."},{"issue":"4","key":"2026090707080706600_cit101","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/bdd.750","article-title":"Diverse Approaches for the Enhancement\nof Oral Drug Bioavailability","volume":"32","author":"Fasinu","year":"2011","journal-title":"Biopharm. Drug\nDispos."},{"issue":"3","key":"2026090707080706600_cit102","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1021\/mp100012s","article-title":"Paclitaxel\nNanocrystals for Overcoming\nMultidrug Resistance in Cancer","volume":"7","author":"Liu","year":"2010","journal-title":"Mol. Pharmaceutics"},{"key":"2026090707080706600_cit103","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.ijpharm.2019.05.064","article-title":"Development\nof Sorafenib\nLoaded Nanoparticles to Improve Oral Bioavailability Using a Quality\nby Design Approach","volume":"566","author":"Park","year":"2019","journal-title":"Int. J. Pharm."},{"issue":"1","key":"2026090707080706600_cit104","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.xphs.2016.09.014","article-title":"Pharmaceutical Amorphous\nNanoparticles","volume":"106","author":"Jog","year":"2017","journal-title":"J. Pharm. Sci."},{"issue":"1","key":"2026090707080706600_cit105","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.ijpharm.2017.09.031","article-title":"Development of an Abiraterone\nAcetate Formulation with\nImproved Oral Bioavailability Guided by Absorption Modeling Based\non in Vitro Dissolution and Permeability Measurements","volume":"532","author":"Solymosi","year":"2017","journal-title":"Int. J. Pharm."},{"issue":"1\u20132","key":"2026090707080706600_cit106","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.ijpharm.2011.04.034","article-title":"Potent Dried\nDrug Nanosuspensions for Oral Bioavailability Enhancement of Poorly\nSoluble Drugs with PH-Dependent Solubility","volume":"413","author":"Mou","year":"2011","journal-title":"Int. J. Pharm."},{"issue":"1","key":"2026090707080706600_cit107","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.xphs.2021.09.008","article-title":"Lipophilic\nSalts and Lipid-Based Formulations for Bridging the Food Effect Gap\nof Venetoclax","volume":"111","author":"Koehl","year":"2022","journal-title":"J. Pharm. Sci."},{"key":"2026090707080706600_cit108","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/801820","article-title":"Lipid-Based\nDrug Delivery\nSystems","volume":"2014","author":"Shrestha","year":"2014","journal-title":"J. Pharm."},{"issue":"1","key":"2026090707080706600_cit109","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1080\/10717544.2022.2083724","article-title":"Self-Emulsifying Drug Delivery Systems: A Novel Approach\nto Deliver Drugs","volume":"29","author":"Salawi","year":"2022","journal-title":"Drug Deliv."},{"issue":"8","key":"2026090707080706600_cit110","doi-asserted-by":"publisher","first-page":"3609","DOI":"10.1208\/s12249-018-1188-8","article-title":"Lipid-Based Oral Formulation Strategies\nfor Lipophilic Drugs","volume":"19","author":"Patel","year":"2018","journal-title":"AAPS PharmSciTech"},{"issue":"4","key":"2026090707080706600_cit111","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s11095-019-2590-y","article-title":"New Insights\ninto Using Lipid Based Suspensions for Brick Dust\u2019 Molecules:\nCase Study of Nilotinib","volume":"36","author":"Koehl","year":"2019","journal-title":"Pharm. Res."},{"issue":"7","key":"2026090707080706600_cit112","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1007\/s11095-020-02841-9","article-title":"Chase Dosing\nof Lipid Formulations to Enhance Oral Bioavailability of Nilotinib\nin Rats","volume":"37","author":"Koehl","year":"2020","journal-title":"Pharm. Res."},{"issue":"3","key":"2026090707080706600_cit113","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.biopha.2004.02.001","article-title":"Self-Emulsifying Drug\nDelivery Systems\n(SEDDS) for Improved Oral Delivery of Lipophilic Drugs","volume":"58","author":"Neslihan Gursoy","year":"2004","journal-title":"Biomed. Pharmacother."},{"issue":"3","key":"2026090707080706600_cit114","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1080\/03639045.2020.1730398","article-title":"Preparation and Optimization of Nilotinib\nSelf-Micro-Emulsifying Drug Delivery Systems to Enhance Oral Bioavailability","volume":"46","author":"Zakkula","year":"2020","journal-title":"Drug Dev. Ind. Pharm."},{"issue":"9","key":"2026090707080706600_cit115","doi-asserted-by":"publisher","first-page":"3202","DOI":"10.1021\/acs.molpharmaceut.0c00305","article-title":"Exploring the Impact of Surfactant Type and Digestion:\nHighly Digestible Surfactants Improve Oral Bioavailability of Nilotinib","volume":"17","author":"Koehl","year":"2020","journal-title":"Mol. Pharmaceutics"},{"issue":"31","key":"2026090707080706600_cit116","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.2174\/03666220606143443","article-title":"Self-Emulsifying Drug\nDelivery System for Oral Anti-cancer Therapy: Constraints and Recent\nDevelopment","volume":"28","author":"Pandya","year":"2022","journal-title":"Curr. Pharm. Des."},{"issue":"2","key":"2026090707080706600_cit117","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jconrel.2007.07.018","article-title":"The Utility\nof Cyclodextrins\nfor Enhancing Oral Bioavailability","volume":"123","author":"Carrier","year":"2007","journal-title":"J. Controlled\nRelease"},{"issue":"3","key":"2026090707080706600_cit118","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3390\/pharmaceutics17030288","article-title":"Cyclodextrins:\nEnhancing Drug Delivery,\nSolubility and Bioavailability for Modern Therapeutics","volume":"17","author":"Nicolaescu","year":"2025","journal-title":"Pharmaceutics"},{"issue":"1\u20132","key":"2026090707080706600_cit119","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ijpharm.2017.11.018","article-title":"Cyclodextrins:\nStructure,\nPhysicochemical Properties and Pharmaceutical Applications","volume":"535","author":"Jansook","year":"2018","journal-title":"Int. J. Pharm."},{"issue":"14","key":"2026090707080706600_cit120","doi-asserted-by":"publisher","first-page":"5610","DOI":"10.3390\/molecules28145610","article-title":"Application of Cyclodextrin\nfor Cancer\nImmunotherapy","volume":"28","author":"Wei","year":"2023","journal-title":"Molecules"},{"issue":"9","key":"2026090707080706600_cit121","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.3390\/pharmaceutics15092345","article-title":"Cyclodextrin Inclusion Complexes\nfor Improved Drug Bioavailability and Activity: Synthetic and Analytical\nAspects","volume":"15","author":"Sarabia-Vallejo","year":"2023","journal-title":"Pharmaceutics"},{"issue":"1\u20132","key":"2026090707080706600_cit122","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s10847-014-0447-x","article-title":"Nano-Amorphous Composites of Cilostazol-HP-\u03b2-CD\nInclusion Complexes: Physicochemical Characterization, Structure Elucidation,\nThermodynamic Studies and in Vitro Evaluation","volume":"81","author":"Desai","year":"2015","journal-title":"J. Incl. Phenom. Macrocycl. Chem."},{"issue":"1","key":"2026090707080706600_cit123","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s10973-024-13922-x","article-title":"Effect of Substituted\nCyclodextrins\non Ibrutinib Solubility and Characterization of IBR-Cyclodextrin Inclusion\nComplexes by Isothermal Titration Calorimetry in Solution State","volume":"150","author":"Swarna","year":"2025","journal-title":"J. Therm. Anal. Calorim."},{"key":"2026090707080706600_cit124","doi-asserted-by":"publisher","first-page":"119396","DOI":"10.1016\/j.ijpharm.2020.119396","article-title":"Sulfobutylether-\u03b2-Cyclodextrin","volume":"583","author":"Stella","year":"2020","journal-title":"Int. J. Pharm."},{"issue":"1","key":"2026090707080706600_cit125","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s11095-015-1762-7","article-title":"Assessment\nof Age-Related\nChanges in Pediatric Gastrointestinal Solubility","volume":"33","author":"Maharaj","year":"2016","journal-title":"Pharm. Res."},{"key":"2026090707080706600_cit126","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.addr.2013.10.006","article-title":"Paediatric\nOral Biopharmaceutics:\nKey Considerations and Current Challenges","volume":"73","author":"Batchelor","year":"2014","journal-title":"Adv.\nDrug Deliv. Rev."},{"issue":"12","key":"2026090707080706600_cit127","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1002\/jps.2600811208","article-title":"Gastric Emptying of\nTablets and Granules\nin Humans, Dogs, Pigs, and Stomach-Emptying-Controlled Rabbits","volume":"81","author":"Aoyagi","year":"1992","journal-title":"J. Pharm. Sci."},{"key":"2026090707080706600_cit128","doi-asserted-by":"publisher","first-page":"105840","DOI":"10.1016\/j.ejps.2021.105840","article-title":"Combining Species\nSpecific in Vitro & in Silico Models to Predict in Vivo Food Effect\nin a Preclinical Stage - Case Study of Venetoclax","volume":"162","author":"Henze","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"issue":"4","key":"2026090707080706600_cit129","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1111\/cts.13209","article-title":"Effect of Food on Capsule and Granule\nFormulations\nof Selumetinib","volume":"15","author":"Cohen-Rabbie","year":"2022","journal-title":"Clin. Transl. Sci."},{"issue":"5","key":"2026090707080706600_cit130","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/cpdd.1051","article-title":"Relative Bioavailability\nand Food Effect of GSK3640254 Tablet and Capsule Formulations in Healthy\nParticipants","volume":"11","author":"Johnson","year":"2022","journal-title":"Clin. Pharmacol. Drug Dev."},{"issue":"2","key":"2026090707080706600_cit131","doi-asserted-by":"publisher","first-page":"87","DOI":"10.4103\/0976-500X.72350","article-title":"Blood Sample Collection in Small\nLaboratory Animals","volume":"1","author":"Parasuraman","year":"2010","journal-title":"J. Pharmacol. Pharmacother."},{"key":"2026090707080706600_cit132","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ctrv.2016.09.012","article-title":"Inventory\nof Oral Anti-cancer Agents: Pharmaceutical Formulation Aspects with\nFocus on the Solid Dispersion Technique","volume":"50","author":"Sawicki","year":"2016","journal-title":"Cancer\nTreat. Rev."},{"key":"2026090707080706600_cit133","volume-title":"Labeling-Package\nInsert, Mercaptopurine\nTablet","author":"Hikma Pharmaceuticals USA Inc.","year":"1953"},{"key":"2026090707080706600_cit134","volume-title":"Labeling-Package Insert, Dabrafenib Capsule\n(TAFINLAR)","author":"Novartis Pharmaceuticals Corporation.","year":"2013"},{"key":"2026090707080706600_cit135","volume-title":"Labeling-Package Insert, Cabozantinib Tablet (CABOMETYX)","author":"Exelixis.","year":"2012"},{"key":"2026090707080706600_cit136","volume-title":"Labeling-Package Insert Trametinib Tablet,\nTrametinib Powder for Solution (MEKINIST)","author":"Novartis Pharmaceuticals Corporation.","year":"2023"},{"key":"2026090707080706600_cit137","volume-title":"Labeling-Package\nInsert, Methotrexate Sodium\nTablet","author":"Hikma Pharmaceuticals USA Inc.","year":"1953"},{"key":"2026090707080706600_cit138","volume-title":"Labeling-Package Insert, Bosutinib\nTablet (BOSULIF)","author":"Pfizer Laboratories Div. Pfizer Inc.","year":"2012"},{"key":"2026090707080706600_cit139","volume-title":"Labeling-Package Insert, Selumetinib\nCapsule (KOSELUGO)","author":"AstraZeneca Pharmaceuticals LP.","year":"2020"},{"key":"2026090707080706600_cit140","volume-title":"Centre for Drug Evaluation and Research,\nNDA Application No. 213756, Product Quality Review(s), Approval","author":"Selumetinib Capsule (KOSELUGO).","year":"2020"},{"key":"2026090707080706600_cit141","volume-title":"Labeling-Package Insert, Crizotinib\nCapsule (XALKORI)","author":"Pfizer Laboratories Div. Pfizer Inc.","year":"2023"},{"key":"2026090707080706600_cit142","doi-asserted-by":"publisher","first-page":"100020","DOI":"10.1016\/j.pscia.2023.100020","article-title":"Biowaiver Based\non Biopharmaceutics Classification System: Considerations and Requirements","volume":"2","author":"Dhake","year":"2024","journal-title":"Pharm. Sci. Adv."},{"key":"2026090707080706600_cit143","doi-asserted-by":"publisher","first-page":"105549","DOI":"10.1016\/j.ejps.2020.105549","article-title":"BCS-Based\nBiowaivers: Extension to Paediatrics","volume":"155","author":"Martir","year":"2020","journal-title":"Eur. J.\nPharm. Sci."},{"issue":"4","key":"2026090707080706600_cit144","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.xphs.2016.12.018","article-title":"Medicines\nfor Pediatric\nPatients-Biopharmaceutical, Developmental, and Regulatory Considerations","volume":"106","author":"Elder","year":"2017","journal-title":"J. Pharm. Sci."},{"issue":"2","key":"2026090707080706600_cit145","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.ijpharm.2016.06.115","article-title":"Towards the Development\nof a Paediatric Biopharmaceutics Classification System: Results of\na Survey of Experts","volume":"511","author":"Batchelor","year":"2016","journal-title":"Int. J. Pharm."},{"issue":"3","key":"2026090707080706600_cit146","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1208\/s12248-010-9206-0","article-title":"Meeting Report: Applied Biopharmaceutics\nand Quality by Design for\nDissolution\/Release Specification Setting: Product Quality for Patient\nBenefit","volume":"12","author":"Selen","year":"2010","journal-title":"AAPS J."},{"issue":"3","key":"2026090707080706600_cit147","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1208\/s12249-014-0084-0","article-title":"Considerations\nfor a Pediatric Biopharmaceutics Classification System (BCS): Application\nto Five Drugs","volume":"15","author":"Gandhi","year":"2014","journal-title":"AAPS PharmSciTech"},{"issue":"11","key":"2026090707080706600_cit148","doi-asserted-by":"publisher","first-page":"567","DOI":"10.3390\/pharmaceutics11110567","article-title":"Classification of WHO\nEssential Oral\nMedicines for Children Applying a Provisional Pediatric Biopharmaceutics\nClassification System","volume":"11","author":"delMoral-Sanchez","year":"2019","journal-title":"Pharmaceutics"},{"issue":"6","key":"2026090707080706600_cit149","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1111\/j.1476-5381.2009.00267.x","article-title":"To Scale or Not\nto Scale: The Principles\nof Dose Extrapolation","volume":"157","author":"Sharma","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"2026090707080706600_cit150","volume-title":"Labeling-Package\nInsert, Imatinib Mesylate\nTablet (GLEEVEC)","author":"Novartis Pharmaceuticals Corporation.","year":"2001"},{"issue":"2","key":"2026090707080706600_cit151","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1177\/0091270003262101","article-title":"Absolute Bioavailability of Imatinib (Glivec) Orally versus Intravenous\nInfusion","volume":"44","author":"Peng","year":"2004","journal-title":"J. Clin. Pharmacol."},{"key":"2026090707080706600_cit152","volume-title":"Product-Specific\nBioequivalence Guidance\nfor Imatinib Hard Capsules 50 and 100 mg, Film-Coated Tablets 100\nand 400 mg","author":"European Medicines Agency.","year":"2015"},{"key":"2026090707080706600_cit153","volume-title":"Labeling-Package Insert, Imatinib Oral Solution\n(IMKELDI)","author":"Shorla Oncology Inc.","year":"2001"},{"key":"2026090707080706600_cit154","volume-title":"Labeling-Package Insert, Cyclophosphamide\nTablet","author":"Baxter Healthcare Corporation.","year":"1959"},{"key":"2026090707080706600_cit155","volume-title":"Labeling-Package Insert, Procarbazine Hydrochloride\nCapsule (MATULANE)","author":"Leadiant Biosciences.","year":"1969"},{"key":"2026090707080706600_cit156","volume-title":"Labeling-Package Insert, Capecitabine Tablet (XELODA)","author":"Genentech.","year":"1998"},{"key":"2026090707080706600_cit157","volume-title":"Guideline on Pharmaceutical Development\nof Medicines for Paediatric Use","author":"European Medicines Agency.","year":"2013"},{"issue":"4","key":"2026090707080706600_cit158","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1208\/s12248-013-9509-z","article-title":"Impact of Osmotically\nActive Excipients on Bioavailability and Bioequivalence of BCS Class\nIII Drugs","volume":"15","author":"Chen","year":"2013","journal-title":"AAPS J."},{"issue":"6","key":"2026090707080706600_cit159","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1111\/bcp.13227","article-title":"Dose Evaluation\nof Lamivudine in Human Immunodeficiency Virus-Infected Children Aged\n5 Months to 18 Years Based on a Population Pharmacokinetic Analysis","volume":"83","author":"Janssen","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"2026090707080706600_cit160","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.ijpharm.2013.09.013","article-title":"The STEP (Safety\nand Toxicity of Excipients for Paediatrics) Database: Part 2 - The\nPilot Version","volume":"457","author":"Salunke","year":"2013","journal-title":"Int. J. Pharm."},{"key":"2026090707080706600_cit161","first-page":"1","volume-title":"EMEA","author":"Committee for Medicinal Products for Human Use (CHMP) Guideline.","year":"2008"},{"issue":"5","key":"2026090707080706600_cit162","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/j.1753-4887.1987.tb02707.x","article-title":"Mystery of the E-Ferol Syndrome","volume":"45","year":"1987","journal-title":"Nutr. Rev."},{"key":"2026090707080706600_cit163","volume-title":"Docusate Sodium","author":"Hannoodee","year":"2023"},{"issue":"3","key":"2026090707080706600_cit164","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/S0022-3476(78)81183-4","article-title":"Central Nervous\nSystem Toxicity Associated\nwith Ingestion of Propylene Glycol","volume":"93","author":"Arulanantham","year":"1978","journal-title":"J. Pediatr."},{"issue":"6","key":"2026090707080706600_cit165","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/(SICI)1099-1557(199910\/11)8:6&lt;377::AID-PDS448&gt;3.0.CO;2-C","article-title":"Pathogenesis of\nFibrosing Colonopathy:\nThe Role of Methacrylic Acid Copolymer","volume":"8","author":"Prescott","year":"1999","journal-title":"Pharmacoepidemiol.\nDrug Saf."},{"issue":"1","key":"2026090707080706600_cit166","doi-asserted-by":"publisher","DOI":"10.2903\/j.efsa.2020.5969","article-title":"Safety of\nUse of Oat Lecithin as a Food Additive","volume":"18","author":"Younes","year":"2020","journal-title":"EFSA\nJ."},{"issue":"4","key":"2026090707080706600_cit167","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.aller.2011.06.005","article-title":"Anaphylactic\nReaction to Povidone\nSecondary to Drug Ingestion in a Young Child","volume":"40","author":"Michavila-Gomez","year":"2012","journal-title":"Allergol. Immunopathol."},{"issue":"6","key":"2026090707080706600_cit168","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/j.1365-2125.2005.02410.x","article-title":"Formulation of Medicines for Children","volume":"59","author":"Nunn","year":"2005","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"2026090707080706600_cit169","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.otot.2015.01.007","article-title":"Pediatric\nOral Anatomy","volume":"26","author":"Shah","year":"2015","journal-title":"Oper. Tech. Otolaryngol. Neck\nSurg."},{"issue":"12","key":"2026090707080706600_cit170","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/psb.1371","article-title":"Medication Adherence in Children\nRemains a Challenge","volume":"26","author":"Chappell","year":"2015","journal-title":"Prescriber"},{"key":"2026090707080706600_cit171","unstructured":"U.S. Department of Health and Human Services; USFDA.\n          , Guidance\nfor Industry; Size, Shape, and Other Physical Attributes of Generic\nTablets and Capsules. https:\/\/www.fda.gov\/media\/87344\/download (accessed May 31, 2026)."},{"issue":"6","key":"2026090707080706600_cit172","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s00431-012-1872-8","article-title":"Educational\nPaper: Formulation-Related\nIssues in Pediatric Clinical Pharmacology","volume":"172","author":"Tuleu","year":"2013","journal-title":"Eur.\nJ. Pediatr."},{"issue":"2","key":"2026090707080706600_cit173","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1208\/s12249-016-0558-3","article-title":"Paediatric\nDrug Development and Formulation Design-a European Perspective","volume":"18","author":"Van Riet-Nales","year":"2017","journal-title":"AAPS PharmSciTech"},{"issue":"1","key":"2026090707080706600_cit174","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.ijpharm.2013.07.074","article-title":"Bridging Studies in Support of Oral Pediatric Formulation\nDevelopment","volume":"457","author":"Ricci","year":"2013","journal-title":"Int. J. Pharm."},{"issue":"3\u20134","key":"2026090707080706600_cit175","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.ejps.2006.05.001","article-title":"Review of Global Regulations Concerning Biowaivers\nfor Immediate Release Solid Oral Dosage Forms","volume":"29","author":"Gupta","year":"2006","journal-title":"Eur. J. Pharm. Sci."},{"issue":"3","key":"2026090707080706600_cit176","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1208\/s12248-012-9364-3","article-title":"Biopharmaceutic Planning in Pediatric Drug Development","volume":"14","author":"Purohit","year":"2012","journal-title":"AAPS J."},{"issue":"8","key":"2026090707080706600_cit177","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1136\/gut.27.8.886","article-title":"Transit of Pharmaceutical\nDosage Forms through the Small Intestine","volume":"27","author":"Davis","year":"1986","journal-title":"Gut"},{"key":"2026090707080706600_cit178","doi-asserted-by":"publisher","first-page":"121501","DOI":"10.1016\/j.ijpharm.2022.121501","article-title":"Paediatric Specific Dosage Forms:\nPatient and Formulation\nConsiderations","volume":"616","author":"Khan","year":"2022","journal-title":"Int. J. Pharm."},{"issue":"5","key":"2026090707080706600_cit179","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1080\/08880018.2020.1740844","article-title":"Sorafenib\nin Pediatric Hepatocellular Carcinoma from a Clinician Perspective","volume":"37","author":"Pearson","year":"2020","journal-title":"Pediatr. Hematol. Oncol."},{"key":"2026090707080706600_cit180","unstructured":"Epizyme.\n          . Drug Label Information, Tazemetostat\ntablet (TAZVERIK), https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=7db07b5f-4e22-467c-9c0a-f830b08dbb1d (accessed May 31, 2026)."}],"container-title":["Molecular Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.molpharmaceut.5c00642","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/23\/9\/4394\/67412436\/acs.molpharmaceut.5c00642.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/23\/9\/4394\/67412436\/acs.molpharmaceut.5c00642.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:10:13Z","timestamp":1788779413000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article\/23\/9\/4394\/5329297\/Insight-into-the-Development-of-Desirable-Dosage"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":180,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,8,26]]},"published-print":{"date-parts":[[2026,9,7]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.molpharmaceut.5c00642","relation":{},"ISSN":["1543-8384","1543-8392"],"issn-type":[{"value":"1543-8384","type":"print"},{"value":"1543-8392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]}}}